Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study

por Umezawa, Yoshinori, Sakurai, Shinya, Hoshii, Naoki, Nakagawa, Hidemi
Publicado 2021

Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results

por Okubo, Yukari, Umezawa, Yoshinori, Sakurai, Shinya, Hoshii, Naoki, Nakagawa, Hidemi
Publicado 2022

Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy

por Imafuku, Shinichi, Tada, Yayoi, Umezawa, Yoshinori, Sakurai, Shinya, Hoshii, Naoki, Nakagawa, Hidemi
Publicado 2021

Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results

por Umezawa, Yoshinori, Asahina, Akihiko, Imafuku, Shinichi, Tada, Yayoi, Sano, Shigetoshi, Morita, Akimichi, Sakurai, Shinya, Hoshii, Naoki, Tilt, Nicola, Nakagawa, Hidemi
Publicado 2021